EKF Diagnostics (EKF) Q4 2025 TU earnings summary

Executive summary

• FY 2025 established a strong base for a five-year growth strategy targeting global leadership in POC Hematology, ß-HB supply, and Life Sciences CDMO transformation.

• Focus on higher margin products and core operations, with non-core and low margin lines being wound down.

Financial highlights

• Revenue increased 3% year-over-year to £51.6m (FY 2024: £50.2m).

• Adjusted EBITDA up nearly 10% to £12.4m, in line with consensus forecasts.

• Gross margin improved to 51% from 48% in the prior year.

• Cash at year-end was £15.8m, up from £14.3m, after £5.1m spent on share buy-backs and growth investments.

• No bank borrowings reported.

Outlook and guidance

• New fermentation development agreement expected to drive further revenue growth into 2026 and potential US onshore expansion.

• FY 2025 results to be announced in late March 2026.